Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Accounts Payables (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Accounts Payables for 16 consecutive years, with $2.9 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 36.25% to $2.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 million through Dec 2025, up 36.25% year-over-year, with the annual reading at $2.9 million for FY2025, 36.25% up from the prior year.
  • Accounts Payables hit $2.9 million in Q4 2025 for Ironwood Pharmaceuticals, up from $1.6 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $7.8 million in Q4 2023 to a low of $118000.0 in Q1 2023.
  • Historically, Accounts Payables has averaged $2.4 million across 5 years, with a median of $1.5 million in 2025.
  • Biggest five-year swings in Accounts Payables: tumbled 77.85% in 2021 and later skyrocketed 5172.88% in 2024.
  • Year by year, Accounts Payables stood at $935000.0 in 2021, then tumbled by 48.34% to $483000.0 in 2022, then surged by 1521.12% to $7.8 million in 2023, then crashed by 72.84% to $2.1 million in 2024, then skyrocketed by 36.25% to $2.9 million in 2025.
  • Business Quant data shows Accounts Payables for IRWD at $2.9 million in Q4 2025, $1.6 million in Q3 2025, and $1.4 million in Q2 2025.